Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks.

Menniti FS, Lindsley CW, Conn PJ, Pandit J, Zagouras P, Volkmann RA.

Curr Top Med Chem. 2013;13(1):26-54. Review.

2.

Targeting glutamate synapses in schizophrenia.

Field JR, Walker AG, Conn PJ.

Trends Mol Med. 2011 Dec;17(12):689-98. doi: 10.1016/j.molmed.2011.08.004. Epub 2011 Sep 28. Review.

3.

[Evidence on the key role of the metabotrobic glutamatergic receptors in the pathogenesis of schizophrenia: a "breakthrough" in pharmacological treatment].

Pannese R, Minichino A, Pignatelli M, Delle Chiaie R, Biondi M, Nicoletti F.

Riv Psichiatr. 2012 Mar-Apr;47(2):149-69. doi: 10.1708/1069.11719. Review. Italian.

PMID:
22622251
4.

Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia.

Lindsley CW, Shipe WD, Wolkenberg SE, Theberge CR, Williams DL Jr, Sur C, Kinney GG.

Curr Top Med Chem. 2006;6(8):771-85. Review.

PMID:
16719816
5.

Recent patents on positive allosteric modulators of the metabotropic glutamate 5 receptor as a potential treatment for schizophrenia.

Kanuma K, Aoki T, Shimazaki Y.

Recent Pat CNS Drug Discov. 2010 Jan;5(1):23-34. Review.

PMID:
19832691
6.

Metabotropic glutamate receptor 5 in the pathology and treatment of schizophrenia.

Matosin N, Newell KA.

Neurosci Biobehav Rev. 2013 Mar;37(3):256-68. doi: 10.1016/j.neubiorev.2012.12.005. Epub 2012 Dec 17. Review.

PMID:
23253944
7.

Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?

Marek GJ, Behl B, Bespalov AY, Gross G, Lee Y, Schoemaker H.

Mol Pharmacol. 2010 Mar;77(3):317-26. doi: 10.1124/mol.109.059865. Epub 2009 Nov 23. Review. Erratum in: Mol Pharmacol. 2010 May;77(5):884.

8.

Metabotropic glutamate receptors as therapeutic targets for schizophrenia.

Vinson PN, Conn PJ.

Neuropharmacology. 2012 Mar;62(3):1461-72. doi: 10.1016/j.neuropharm.2011.05.005. Epub 2011 May 19. Review.

9.

Drug development in schizophrenia: are glutamatergic targets still worth aiming at?

Goff DC.

Curr Opin Psychiatry. 2015 May;28(3):207-15. doi: 10.1097/YCO.0000000000000152. Review.

PMID:
25710242
10.

Targeting of metabotropic glutamate receptors for the treatment of schizophrenia.

Chaki S, Hikichi H.

Curr Pharm Des. 2011;17(2):94-102. Review.

PMID:
21355835
11.

Antischizophrenic activity independent of dopamine D2 blockade.

Kalkman HO.

Expert Opin Ther Targets. 2002 Oct;6(5):571-82. Review.

PMID:
12387681
12.

Group 5 metabotropic glutamate receptors: role in modulating cortical activity and relevance to cognition.

Homayoun H, Moghaddam B.

Eur J Pharmacol. 2010 Aug 10;639(1-3):33-9. doi: 10.1016/j.ejphar.2009.12.042. Epub 2010 Apr 2. Review.

PMID:
20371231
13.

[Glutamate hypothesis of schizophrenia and targets for new antipsychotic drugs].

Hashimoto K, Iyo M.

Nihon Shinkei Seishin Yakurigaku Zasshi. 2002 Feb;22(1):3-13. Review. Japanese.

PMID:
11917507
14.

Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials.

Iwata Y, Nakajima S, Suzuki T, Keefe RS, Plitman E, Chung JK, Caravaggio F, Mimura M, Graff-Guerrero A, Uchida H.

Mol Psychiatry. 2015 Oct;20(10):1151-60. doi: 10.1038/mp.2015.68. Epub 2015 Jun 16. Review.

15.

From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment.

Moghaddam B, Javitt D.

Neuropsychopharmacology. 2012 Jan;37(1):4-15. doi: 10.1038/npp.2011.181. Epub 2011 Sep 28. Review.

16.

[Role of astrocytes in alterations of glutamatergic neurotransmission in schizophrenia].

Kolomeets NS.

Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(1):110-117. doi: 10.17116/jnevro201511511110-117. Review. Russian.

PMID:
25945378
17.

Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia.

Fell MJ, McKinzie DL, Monn JA, Svensson KA.

Neuropharmacology. 2012 Mar;62(3):1473-83. doi: 10.1016/j.neuropharm.2011.06.007. Epub 2011 Jun 21. Review.

PMID:
21704048
18.

Glutamatergic theories of schizophrenia.

Javitt DC.

Isr J Psychiatry Relat Sci. 2010;47(1):4-16. Review.

19.
20.

Metabotropic glutamate receptors for new treatments in schizophrenia.

Herman EJ, Bubser M, Conn PJ, Jones CK.

Handb Exp Pharmacol. 2012;(213):297-365. doi: 10.1007/978-3-642-25758-2_11. Review.

PMID:
23027420

Supplemental Content

Support Center